MPM BIOIMPACT LLC
Long book
$1.29B
Q1 2026
Positions
41
Top-10 weight
49%
concentration
Last quarter
+29.6%
SPY +14.8%
Turnover
39%
of book per quarter
Strategy in plain words
auto-generated from filingsMPM BIOIMPACT LLC is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $1.29B US long book across 41 positions.
The portfolio is moderately concentrated (top 10 ≈ 49% of the book). The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: DBV TECHNOLOGIES SA-SPON ADR, CULLINAN THERAPEUTICS INC, AKTIS ONCOLOGY INC, LIQUIDIA CORP, ALUMIS INC.
Over the last 9 quarters its long book ran on average 1.8pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-8.3%
Q2 2024
+4.0%
Q3 2024
-11.3%
Q4 2024
-18.4%
Q1 2025
+0.1%
Q2 2025
+17.1%
Q3 2025
+29.3%
Q4 2025
+14.0%
Q1 2026
+29.6%
Sector allocation
Healthcare 100%
Long book by quarter
What does MPM BIOIMPACT own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| CGEM CULLINAN THERAPEUTICS INC | Healthcare | 7.6M | $108.7M | 8.4% | Held |
| AKTS AKTIS ONCOLOGY INC | Healthcare | 4.8M | $86.5M | 6.7% | New |
| LQDA LIQUIDIA CORP | Healthcare | 1.4M | $53.0M | 4.1% | +0.3% |
| ALMS ALUMIS INC | Healthcare | 2.4M | $52.6M | 4.1% | -0.6% |
| EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 1.7M | $52.3M | 4.0% | +0.3% |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 506.8K | $49.3M | 3.8% | +0.2% |
| AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 1.3M | $44.2M | 3.4% | +0.2% |
| CORT CORCEPT THERAPEUTICS INC | Healthcare | 985.7K | $39.7M | 3.1% | New |
| TRVI TREVI THERAPEUTICS INC | Healthcare | 3.3M | $39.4M | 3.0% | +0.3% |
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 424.0K | $35.6M | 2.7% | New |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 588.7K | $34.2M | 2.6% | +21.2% |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 1.8M | $33.8M | 2.6% | New |
| TVTX TRAVERE THERAPEUTICS INC | Healthcare | 1.1M | $33.7M | 2.6% | New |
| EVMN EVOMMUNE INC | Healthcare | 1.5M | $33.5M | 2.6% | +1188.1% |
| CYTK CYTOKINETICS INC | Healthcare | 500.0K | $33.0M | 2.5% | New |
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.3M | $31.3M | 2.4% | +0.2% |
| CNTX CONTEXT THERAPEUTICS INC | Healthcare | 10.7M | $28.0M | 2.2% | Held |
| FBRX FORTE BIOSCIENCES INC | Healthcare | 1.0M | $25.9M | 2.0% | New |
| PVLA PALVELLA THERAPEUTICS INC | Healthcare | 206.4K | $25.7M | 2.0% | +0.3% |
| DYN DYNE THERAPEUTICS INC | Healthcare | 1.4M | $25.5M | 2.0% | +0.2% |
| STOK STOKE THERAPEUTICS INC | Healthcare | 767.0K | $25.0M | 1.9% | -0.4% |
| CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 1.7M | $24.5M | 1.9% | -39.0% |
| RLAY RELAY THERAPEUTICS INC | Healthcare | 2.4M | $23.5M | 1.8% | +5.7% |
| TARS TARSUS PHARMACEUTICALS INC | Healthcare | 329.8K | $23.1M | 1.8% | +0.3% |
| ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.8M | $22.9M | 1.8% | +0.3% |
| QURE UNIQURE NV | Healthcare | 1.4M | $22.4M | 1.7% | -0.9% |
| GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 1.2M | $19.4M | 1.5% | +0.3% |
| NTRA NATERA INC | Healthcare | 93.1K | $18.6M | 1.4% | -0.5% |
| CLYM CLIMB BIO INC | Healthcare | 2.6M | $17.8M | 1.4% | -2.9% |
| ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 734.0K | $17.3M | 1.3% | +38.2% |
| URGN UROGEN PHARMA LTD | Healthcare | 943.8K | $17.0M | 1.3% | +0.3% |
| DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 212.2K | $15.5M | 1.2% | -7.8% |
| ZYME ZYMEWORKS INC | Healthcare | 565.2K | $14.2M | 1.1% | New |
| VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 649.9K | $12.7M | 1.0% | New |
| ENGN enGene Therapeutics Inc | Healthcare | 1.8M | $12.6M | 1.0% | +0.2% |
| ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 2.2M | $5.5M | 0.4% | New |
| ACRS ACLARIS THERAPEUTICS INC | Healthcare | 391.9K | $1.5M | 0.1% | New |
| HOWL WEREWOLF THERAPEUTICS INC | Healthcare | 1.2M | $1.0M | 0.1% | -13.3% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 41 | $1.29B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 38 | $874.0M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 40 | $610.9M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 44 | $577.2M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 43 | $581.7M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 47 | $704.4M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 13, 2024 | 43 | $666.6M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 44 | $643.5M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 38 | $622.0M | canonical | SEC ↗ |